This inventor holds 1 USPTO granted patent. Top assignee: Genentech, Inc.. Active years: 1988.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1988
Title: The Innovations of John R Bell
Introduction
John R Bell is a prominent inventor based in San Francisco, CA. He is known for his significant contributions to the field of biochemistry, particularly in the area of insulin receptor research. His work has paved the way for advancements in therapeutic applications related to insulin.
Latest Patents
John R Bell holds a patent for the insulin receptor. This invention involves purifying the insulin receptor to a level sufficient for amino acid sequencing. The patent also provides DNA encoding the insulin receptor and methods for synthesizing the receptor or its mutants in heterologous host cells transformed with vectors containing such DNA. The knowledge of the amino acid sequence enables the preparation of novel immunogenic conjugates and antibodies raised against these conjugates. Additionally, the patent describes novel therapeutically useful forms of the insulin receptor and anti-receptor antibodies.
Career Highlights
John R Bell is associated with Genentech, Inc., a leading biotechnology company. His work at Genentech has been instrumental in advancing the understanding of insulin receptors and their applications in medicine. His innovative approach has contributed to the development of new therapeutic strategies.
Collaborations
Throughout his career, John R Bell has collaborated with notable scientists, including Janakiraman Ramachandran and Axel Ullrich. These collaborations have further enhanced the research and development of insulin-related therapies.
Conclusion
John R Bell's contributions to the field of biochemistry, particularly through his patent on the insulin receptor, have had a lasting impact on medical science. His work continues to inspire advancements in therapeutic applications for insulin-related conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
